This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: University of California. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Innovations of Chae-Seo Rhee in Immunotherapy
Introduction
Chae-Seo Rhee is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of immunotherapy, particularly in the context of head and neck squamous cell carcinomas. With a total of 2 patents, Rhee's work focuses on the intricate mechanisms of Wnt and frizzled receptors.
Latest Patents
Rhee's latest patents include groundbreaking research on "Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas." This research highlights the important roles that diverse receptor-ligand pairs of the Wnt and frizzled families play during embryonic development. The study investigates the mRNA levels and expression levels of five Wnt genes (Wnt-1, 5a, 7a, 10b, 13) and two Fzd genes (Fzd-2, 5) in ten head and neck squamous carcinoma cell lines (HNSCC). The findings indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, suggesting that the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may serve as useful targets for immunotherapy of this common cancer.
Career Highlights
Chae-Seo Rhee has worked with prestigious institutions such as the University of California and Seoul National University. His research has contributed to a deeper understanding of cancer biology and potential therapeutic targets.
Collaborations
Rhee has collaborated with notable colleagues, including Malini Sen and Lorenzo M Leoni. These collaborations have further enriched his research and expanded the impact of his findings in the scientific community.
Conclusion
Chae-Seo Rhee's innovative work in the field of immunotherapy exemplifies the potential of targeting Wnt and frizzled receptors in cancer treatment. His contributions are paving the way for new therapeutic strategies in combating head and neck squamous cell carcinomas.